Daily Archives: January 19, 2021

DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. Nearly every cell in a persons body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA). Mitochondria are structures within cells that convert the energy from food into a form that cells can use.

The information in DNA is stored as a code made up of four chemical bases: adenine (A), guanine (G), cytosine (C), and thymine (T). Human DNA consists of about 3 billion bases, and more than 99 percent of those bases are the same in all people. The order, or sequence, of these bases determines the information available for building and maintaining an organism, similar to the way in which letters of the alphabet appear in a certain order to form words and sentences.

DNA bases pair up with each other, A with T and C with G, to form units called base pairs. Each base is also attached to a sugar molecule and a phosphate molecule. Together, a base, sugar, and phosphate are called a nucleotide. Nucleotides are arranged in two long strands that form a spiral called a double helix. The structure of the double helix is somewhat like a ladder, with the base pairs forming the ladders rungs and the sugar and phosphate molecules forming the vertical sidepieces of the ladder.

An important property of DNA is that it can replicate, or make copies of itself. Each strand of DNA in the double helix can serve as a pattern for duplicating the sequence of bases. This is critical when cells divide because each new cell needs to have an exact copy of the DNA present in the old cell.

Visit link:
What is DNA?: MedlinePlus Genetics

Autoplay

Show Thumbnails

Show Captions

Detroit There may not be a more fitting day to introduce or reintroduce for fans of a more aged vintage new Tigers bench coach George Lombard than on Martin Luther King Day. That's because the late Posy Lombard, a white woman from a wealthy New England family who became a legendary activist in the American civil rights movement, is his mother.

Posy Lombard, who was killed in a car accident at age 41, when George was 10, marched with Dr. King in 1963. She was a congressional intern. She went to civil rights seminars to hear Malcolm X. She was arrested in Montgomery, Ala., in 1965, for protesting the Bloody Sunday beatings in Selma. Later she was arrested twice for protesting racial injustice in Natchez, Miss., where she famously stared down members of the Ku Klux Klan that blocked her attempts at integrating a neighborhood playground. She helped affect positive change in the Deep South.

George Lombard was hired as bench coach by new Tigers manager AJ Hinch.(Photo: Elsa, Getty Images)

Your mom was a bad-ass, former Tiger David Price texted Lombard during the baseball shutdown last summer.

The mention of that text raised goosebumps on George Lombards arms Sunday during a Zoom interview.

More: Tigers sign former Red Sox lefty Robbie Ross to minor-league deal

Just being a difference-maker, said Lombard, who spent the last five years going to three World Series and winning one with the Los Angeles Dodgers last October. Jackie Robinson. Martin Luther King. My mom lived such a short life and impacted so many people.

With my story coming out, it was just a chance to change some minds and to move so many people.

More: Tigers splash cash in signing 17-year-old international shortstops Santana, Bastidas

Lombard, though certainly aware of his mothers history his older brother and younger sister worked to obtain a thick file the FBI had on his Posy had never made her story public, never made it part of his story.

Until COVID-19 happened. Until Ahmaud Arbery, Jacob Black and George Floyd happened. Until Black Lives Matter happened.

A police booking photo of Posy Lombard after she was arrested in Montgomery, Alabama.(Photo: Los Angeles Daily News)

Here we are, 50 years later, and were still fighting the same fight, he said. Which is a bit embarrassing. We all need to wake up and understand what is happening.

Lombard, who played for the Tigers in 2002, spent the early days of the pandemic researching his mothers life. He knew he wanted to use her story as a base for his own advocacy efforts. He knew, as a big-league coach, he had a platform. It just wasnt in his nature to jump up on that platform and speak to large groups.

More: Tigers avoid arbitration with all nine eligible players

Especially about his childhood. Posy was raising the three children by herself. All of a sudden, she was gone and their father, Paul Williams, an autoworker who had been living elsewhere, was moving back in. Lombard remembers being in an Atlanta courtroom and a judge asking him if he wanted to keep the name Lombard or use their fathers name Williams.

More: Ex-Tigers help throw iconic Detroit columnist Pete Waldmeir a 90th birthday bash

Those are tough questions to answer at a young age, he said. But Im 45 now and I realize the decisions Ive made throughout my life had a great deal to do with the way my mother raised us.

Lombard, with the help of renowned mental skills trainer Lucas Jadin, gradually started bringing his and his mothers story into the light. First a feature story in the Los Angeles Daily News. Then ESPN gave it a national ride. Within the clubhouse, Price was the first one Lombard opened up to about it.

Former Tigers pitcher David Price was instrumental in telling players the story of George Lombard's mother Posy, who was a strong advocate in the fight for civil rights.(Photo: Carlos Osorio, AP)

Pricey was great, he was the one who really pushed the story to the players, Lombard said.

After taking part in a peaceful march for justice in Scottsdalethis summer, Price, as reported in the ESPN story, texted Lombard: George, I just wanted to let you know that my family and I did a peaceful protest in honor of your mom's name. I can't tell you how many shapes, sizes, colors, religions, ethnicities however you identify, everybody was out there. We were together as one, and that's the way it needs to be."

More: Power up: Tigers pitcher Michael Fulmer done being skinny

Lombard told ESPN, "I told my wife it was my greatest moment as a coach. I was almost in tears."

Its been the most emotional six months that Ive had, Lombard said on Sunday.

Culminating, of course, with a World Series championship with the Dodgers.

I was part of five years in L.A. where we went to five playoffs and three World Series just to win one, he said. Thats just to explain the difficulty of winning at that level. It was eye-opening.

The Tigers had gotten permission to interview Lombard for the open manager job earlier in the playoffs. And although Lombard made it clear that his sole focus at the time was on trying to win a ring with the Dodgers and he hadnt had time to properly research the Tigers' job, he impressed both general manager Al Avila and assistant general manager David Chadd.

David Chadd called me and said they had hired AJ Hinch, but would I have any interest in being a bench coach, Lombard said. They loved my interview. That came out of the blue because I pictured myself being with the Dodgers for many years.

George Lombard played for the Tigers in 2002.(Photo: Al Bello, Getty Images)

Having won a ring with the Dodgers, having managerial ambitions, with the mutual admiration and history he has with Hinch, and with Detroit a heck of a lot closer to his family in Georgia than Los Angeles it ended up being an easy call to accept the Tigers job.

I have so much gratitude for (Dodgers president) Andrew Friedman and (manager) Dave Roberts for giving me my first Major League coaching job, Lombard said. But they both pushed on me that it was important for me to get into a position where I could start making decisions and take on more responsibility.

And with AJ, I think hes going to be a great person for me to learn from and to teach me the Xs and Os of the game.

Detroit is a trigger point of a lot of memories for Lombard, memories from his playing days. He was traded from the Braves to the Tigers on June 19, 2002. The Braves and Tigers happened to playing each other that day in Atlanta. He just walked from the home clubhouse to the visitor's clubhouse.

Lombard has the distinction of taking batting practice for both teams, first in a Braves uniform and then in a Tigers uniform, before the same game.

Later that summer, Lombard made his first visit to Boston as a big-leaguer. He hadnt been back to New England since the summer his mother died. On July 7, with his mothers family, his grandparents, in the stands, he clubbed a massive home run off pitcher Sun Woo-Kim in the third inning that cleared the wall in center field.

That was unquestionably one of the highlights of my career," he said. "The ball hit off the cameramans leg. The trainer got the ball and his wife did a lot of artwork on it. I still have it.

That was one proud moment for my grandfather, just to see the Lombard name all over the paper. Also, that was the summer Ted Williams died. I have a picture that ran in the Boston Globe of me batting against Pedro Martinez with the flag at half-mast in the background.

And now, as best he can, in his own way, Lombard is carrying the torch of advocacy that his mother helped light 50 years ago.

All of us see things, he said. There are things weve noticed over the last year or so, starting with COVID and the racial injustices. I hope its opened up our eyes to the way we should live our life.

Lombard, above all else, wants to facilitate conversations about justice. He wants to create and sustain awareness. He does it by words and deeds. The cleats he wore last season bore the images of his mother on his left heel and civil rights leader John Lewis on his right.

We can make a difference every day and it doesnt have to be going out and marching for the civil rights movement, he said. It can be as simple as helping out one of your teammates, helping the community or just helping some kid.

We have to be more educated on the subject. I need to be better. I need to teach and overcome some of the things we are going through today. We need to be more educated on that, and thats what I take pride in doing.

Its also, from a leadership standpoint, about listening.

Great leaders are great listeners, he said. Thats where it starts. Before we can open up our minds and hearts, we need to be better listeners. We all know that. But hearing it and reemphasizing it is important.

chris.mccosky@detroitnews.com

Twitter: @cmccosky

Continue reading here:
'We all need to wake up': Advocacy, activism are part of new Tigers coach Lombard's DNA - The Detroit News

Jan. 15, 2021 12:00 UTC

STONY BROOK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences, Inc.(NASDAQ:APDN) (the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its safeCircle pooled surveillance testing service has seen a 158% increase in the daily average number of tests performed to date in January 2021 compared to December 2020. The increase is chiefly the result of the scale-up of certain testing contracts and from the acquisition of new clients. Launched in the fourth quarter of fiscal 2020 (ended September 30, 2020), safeCircle now counts 33 primary/secondary/higher education institutions, private client, local government, and businesses as clients.

Concurrently, the Company stated that it is increasing production of its Linea COVID-19 Assay Kit (the Assay Kit) and sample collection kits to meet expected demand from existing customers, from its safeCircle service that is powered by the Assay Kit, and due to heightened interest in the Assay Kit following a recent U.S. Food & Drug Administrations Food & Drug Administration (FDA) alert that identified the assay as an EUA-approved molecular diagnostic test that can potentially identify certain SARS-CoV-2 mutations (the FDA Alert). The Company also said that Applied DNA Clinical Laboratories, LLC (ADCL), its wholly-owned subsidiary, is on track to submit a request for CLEP-CLIA re-inspection during the current quarter ending March 31, 2021. If granted, CLEP-CLIA certification would enable ADCL to serve as a diagnostic laboratory that would allow for it to conduct diagnostic COVID-19 testing.

Positive business trends for safeCircle have carried over into January and are further enhanced by the growing awareness of our platform regionally and through our partnership with CLEARED4. The profile of prospective clients is changing with more and larger opportunities in our sales pipeline, said Dr. James A. Hayward, president and CEO.

The FDAs recent Alert has the potential to be a catalyst to revenue, concluded Dr. Hayward. We believe our assay is one of the few cost-effective and rapid ways a laboratory can detect S-gene target dropout that serves as a potential indication of a SARS-CoV-2 variant, including the U.K.s B.1.1.7 that is characterized by increased transmissibility. We believe the ability to identify new potential COVID-19 variants with an EUA-approved molecular diagnostic test that is in-market today is essential in the continuing fight against COVID-19. Diagnostic labs using molecular diagnostic tests that do not have the ability to discriminate potential COVID-19 variants from wildtype are unable to quickly and easily identify patients that are potentially infected with a more infectious variant, which we believe may lead to further infection spread.

safeCircle Pooled Surveillance Testing Service

In recent weeks safeCircle has added new clients. They include:

Ramp Up in Production of Kits utilized in COVID-19 Sample Collection

The Company is also increasing the production of sample collection kits utilized in surveillance testing by a factor of four to meet the testing scale-up of the Assay Kits largest customer and for use by new safeCircle clients.

CLEARED4 Partnership Generating New Clients

Applied DNAs recently announced partnership with CLEARED4, a provider of return-to-work health safety solutions, has begun to bear fruit. In addition to being utilized as a mobile-friendly, value-added option for the management of aggregate results testing and reporting to a key safeCircle client, Applied DNA is now providing CLEARED4 services to a second safeCircle client, the aforementioned jewelry company. Applied DNA expects to onboard a third new client this week, the aforementioned private higher education institution. The Company believes that the combination of its safeCircle offering with the CLEARED4 platform is a compelling service in a marketplace that is in search of an accurate, easy-to-employ, faster-turnaround testing service that incents participation.

Linea COVID-19 Assay Kit (Test) Production

The Companys largest customer for its Assay Kit expects to increase its use of the Assay and sample collection kits for its in-house surveillance testing program beginning in early February 2021 to coincide with its campus reopening for the Spring semester. The customers in-house program oversees the weekly surveillance testing of thousands of faculty and staff for the presence of COVID-19. Applied DNA receives recurring replenishment orders from the customer for both Assay and sample collection kits to meet its in-house surveillance testing needs.

In response to the FDA Alert, the Company is relaunching its sales and marketing strategy to center on the Assay Kits potential ability to signal for the presence of a SARS-CoV-2 variant due to S-gene target dropout. Refreshed Frequently Asked Questions are available for reference for prospective diagnostic laboratory customers nationally at https://adnas.com/sars-cov-2-69-70del-mutation-covid-assay-kit/.

Update on Applied DNA Clinical Laboratories (ADCL) CLEP-CLIA Certification

The Company is in the process of completing remediation of deficiencies in ADCLs clinical standard of practice and expects to submit a request for re-inspection during the current quarter ending March 31, 2021. CLEP-CLIA certification will enable ADCL to capture diagnostic COVID-19 revenues currently being conducted by third party clinical labs. CLEP-CLIA certification would also potentially allow ADCL to develop an additional revenue stream through the development and commercialization of a broad-array of diagnostic tests, as laboratory-developed tests (LDTs), that once approved by the applicable regulatory authority, could be offered by ADCL.

About the Linea COVID-19 Assay Kit and Pooled Surveillance Testing

The Linea COVID-19 Assay Kit is authorized by FDA EUA for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory specimens, including anterior nasal swabs, self-collected at a healthcare location or collected by a healthcare worker, and nasopharyngeal and oropharyngeal swabs, mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, and bronchoalveolar lavage (BAL) specimens collected by a healthcare worker from individuals who are suspected of COVID-19 by their healthcare provider. The scope of the Linea COVID-19 Assay Kit EUA, as amended, is expressly limited to use consistent with the Instructions for Use by authorized laboratories, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity tests. The EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated or until the EUAs prior termination or revocation. The diagnostic kit has not been FDA cleared or approved, and the EUAs limited authorization is only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.

The Company is offering surveillance testing in compliance with current CDC, FDA, and CMS guidances. The use of saliva and pooled sampling for surveillance testing, which has been internally validated by the Company in compliance with current surveillance testing guidances, is not included in the Companys EUA authorization for the Linea COVID-19 Assay Kit.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, and pre-clinical nucleic acid-based therapeutic drug candidates.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Companys common stock is listed on NASDAQ under ticker symbol APDN, and its publicly traded warrants are listed on OTC under ticker symbol APPDW.

Applied DNA is a member of the Russell Microcap Index.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be forward-looking in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNAs future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, the possibility that the assay kit could become obsolete or have its utility diminished, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNAs or its partners diagnostic candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration (U.S. FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to U.S. FDA, equivalent foreign regulatory agencies and/or the New York State Department of Health, the unknown limited duration of any Emergency Use Authorization (EUA) approval from U.S. FDA, changes in guidances promulgated by the CDC, U.S. FDA and/or CMS relating to COVID-19 surveillance and diagnostic testing, disruptions in the supply of raw materials and supplies, and various other factors detailed from time to time in Applied DNAs SEC reports and filings, including our Annual Report on Form 10-K filed on December 17, 2020, and other reports we file with the SEC, which are available at http://www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210115005079/en/

Read the original post:
Applied DNA Provides Business Update on COVID-19 Diagnostics and Testing - BioSpace

Understand the influence of COVID-19 on the DNA RNA Extraction Ki market with our analysts monitoring the situation across the globe.DNA RNA Extraction Ki market Analyasis 2021-2027

The DNA RNA Extraction Ki market report studies vital factors about the DNA RNA Extraction Ki that are essential to be understood by existing as well as latest market players. The report highlights the essential elements such as market share, profitability, production, sales, manufacturing, advertising, key market players, regional segmentation, and many more crucial aspects related to the Global DNA RNA Extraction Ki market.

Top Manufacturer Detail Qiagen, Thermo Fisher Scientific, Merck KGaA, Roche, Cytiva, Agilent, Danaher, Promega, Bio-Rad, Bioneer, Akonni Biosystems

The world, millions of people worldwide were infected with COVID-19 disease, and major countries around the world have implemented foot prohibitions and work stoppage orders. Except for the medical supplies and life support products industries, most industries have been greatly impacted, and DNA RNA Extraction Ki industries have also been greatly affected.

Get a Sample Report @:https://www.garnerinsights.com/Global-DNA-RNA-Extraction-Kit-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2020-2027#request-sample

Section (5 6 7): Product Type SegmentationDNA Extraction Kit, RNA Extraction Kit

Industry SegmentationHospital, Laboratory, Other

The report specifically highlights the market share, company profiles, regional outlook, product portfolio, a record of the recent developments, strategic analysis, sales, distribution chain, manufacturing, production as well as advertising, brand value, popular products, demand and supply, and other important factors related to the market to help the new entrants understand the market scenario better.

The report is segmented as follows:

By Region/Country including:

Enquire Here For Discount @https://www.garnerinsights.com/Global-DNA-RNA-Extraction-Kit-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2020-2027#discount

Key features of this report are:

1.It provides valuable insights into theGlobal DNA RNA Extraction Ki market.2.Provides information for the years 2021-2027.Important factors related to the market are mentioned.3.Technological advancements, government regulations, and recent developments are highlighted.4.Advertising and marketing strategies, market trends, and analysis are studied in this report.5.Growth analysis and predictions until the year 2027.6.Statistical analysis of the key players in the market is highlighted.7.Extensively researched market overview.

Other features of the report:

1.Gives a thorough analysis of the key strategies with focus on the corporate structure, R&D methods, localization strategies, production capabilities, sales and performance in various companies.2.Provides valuable insights of the product portfolio, including product planning, development and positioning.3.Analyses the role of key DNA RNA Extraction Ki market players and their partnerships, mergers and acquisitions.

View Full Report of DNA RNA Extraction Ki market@ https://garnerinsights.com/Global-DNA-RNA-Extraction-Kit-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2020-2027

About Us:Garner Insights is a Market Intelligence and consulting firm with an all-inclusive experience and vast knowledge of the market research industry. Our vast storage of research reports across various categories, gives you a complete view of the ever changing and developing trends and current topics worldwide. Our constant endeavor is to keep on improving our storage information by providing rich market reports and constantly improving them.

Contact Us:Mr. Kevin Thomas+1 513 549 5911 (US)+44 203 318 2846 (UK)Email: sales@garnerinsights.com

Read the rest here:
Significant Growth of DNA RNA Extraction Ki Market Will Grow at a Healthy CAGR by 2027 Along with Top Key Players Qiagen, Thermo Fisher Scientific,...

DNA Repair Drugs Market: Introduction

Read Report Overview - https://www.transparencymarketresearch.com/dna-repair-drugs-market.html

Key Drivers and Opportunities of Global DNA Repair Drugs Market

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=77165

Request for Analysis of COVID-19 Impact on DNA Repair Drugs Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=77165

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=77165

North America to Capture Major Share of Global DNA Repair Drugs Market

Pre Book DNA Repair Drugs Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=77165&ltype=S

Key Players Operating in Global DNA Repair Drugs Market

The global DNA repair drugs market is highly concentrated due to the presence of key players. A large number of manufacturers hold major share in their respective regions. Demand for technologically advaced products has increased in emerging as well as developed markets, owing to rise in prevalence of cancer. Growth strategies adopted by leading players are likely to drive the global market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

See original here:
DNA Repair Drugs Market: Rise in prevalence of cancer among population is likely to fuel the growth of the market - BioSpace